Aclaris Therapeutics, Inc. (ACRS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aclaris Therapeutics, Inc. (ACRS) closed at USD 3.38 on 2026-10-14, a change of +41.4 % over the past year, with a market capitalization of USD 513.72M.

Aclaris Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aclaris Therapeutics, Inc. key figures

Previous close

USD 3.38 (2026-10-14)

1-year change

+41.4 %

Market cap

USD 513.72M

Enterprise value

USD 424.02M

P/E ratio (trailing)

-5.92

P/E ratio (forward)

-4.43

EPS (trailing)

-0.59

EPS (forward)

-0.79

PEG ratio

n/a

Price to book

3.92

Revenue growth

-8.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.83

Employees

69

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aclaris Therapeutics, Inc. and compare it with other stocks.